CD24Fc in the Treatment of COVID-19

A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment

Clinical Trial Protocol ID:

04317040

Clinical Trial Investigator Name:

Juan D. Pulido, MD

Clinical Trial Protocol Description:

This Phase III study evaluates the safety and efficacy of adding CD24Fc to COVID-19 best available treatment by comparing COVID disease status improvement time between CD24Fc and placebo arms in 28 days.

Clinical Trial Eligibility Criteria:

In order to participate, you must meet the following criteria:

• Should be at least 18 years of age.
• Diagnosed with COVID-19 and confirmed SARS-CoV-2 viral infection, prior positive viral results allowed.
• Able to sign the consent form.
• Hospitalized and requiring oxygen support, NIAID 8-point ordinal score 3 to 4, regardless of ARDS
• Women of childbearing potential, under the age of 54 years, who use adequate contraception and who agree to use adequate contraception for the duration of the study.

*This is a partial list of eligibility requirements.